Patent ID: 11885807
Assignee: AUTOLUS LIMITED
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC A  C  G

Claim 0:
1. A method of depleting malignant T-cells in a human subject with a TRBC2 positive T-cell lymphoma or leukaemia, the method comprising:
determining the percentage of total T-cells in a sample from the subject which is TRBC1 positive and determining the percentage of total T-cells in the sample which is TRBC2 positive,
detecting a percentage of TRBC1 positive T-cells that is greater than 80% or detecting a percentage of TRBC2 positive T-cells that is greater than 80%,
diagnosing the subject as having a TRBC2 positive T-cell lymphoma or leukaemia when the percentage of TRBC2 positive cells is greater than 80%, and
selectively depleting T-cells in the subject determined to have the TRBC2 positive T cell lymphoma or leukaemia by administering an agent that selectively binds to and depletes malignant and normal T cells that are TRBC2-positive,
wherein the agent is an engineered T-cell expressing a CAR which selectively binds TRBC2 and which comprises: (i) a spacer comprising an IgG1 hinge or a CD8 stalk, and (ii) an endodomain comprising a CD28 co-stimulatory component and a CD3-Zeta component.